In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer–5-fluorouracil conjugates

2008 ◽  
Vol 70 (3) ◽  
pp. 770-776 ◽  
Author(s):  
Fang Yuan ◽  
Xuan Qin ◽  
Dan Zhou ◽  
Qing-Yu Xiang ◽  
Min-Ting Wang ◽  
...  
1997 ◽  
Vol 52 (1-2) ◽  
pp. 49-54 ◽  
Author(s):  
Daniel N. Kushev ◽  
Nadejda C. Spassovska ◽  
Svetoslav I. Taxirov ◽  
Konstantin C. Grancharov

AbstractNew platinum(II) complexes of cyclohexanecarboxylic acid hydrazide (chcah) were synthesized and characterized by elemental analysis, IR. and 1H NMR spectra. Their inhibitory effects on cell growth and macromolecular synthesis of Friend leukemia cells in culture as well as the in vivo antitumor activity towards L1210 leukemia in mice were compared with those of complexes containing differently substituted aromatic acid hydrazides. Some of the complexes exhibited antineoplastic activity. No correlation between the in vitro cytotoxicity and the in vivo antitumor activity was found. However, there was a relationship between the in vitro macromolecular synthesis inhibition profile and the in vivo antineoplastic effect, similar to that of cisplatin. On the other hand, only agents containing one ammine ligand were active in vivo. The substitution of the aromatic ring by a cycloalkane residue increased significantly the antitumor effect, with [Pt(NH3)(chcah)Cl2] being the most active compound in this study.


2005 ◽  
Vol 57 (10) ◽  
pp. 1279-1287 ◽  
Author(s):  
Yan-Li Hao ◽  
Ying-Jie Deng ◽  
Yan Chen ◽  
Ai-Jun Hao ◽  
Yong Zhang ◽  
...  

2015 ◽  
Vol 7 (2) ◽  
pp. 198 ◽  
Author(s):  
C Gayatri ◽  
CUma Maheswara Reddy ◽  
K Chitra ◽  
V Parthasarathy

2020 ◽  
Author(s):  
Ye Wang ◽  
Xin Yang ◽  
Hong Li ◽  
Haiyang Xie

Abstract Background: Osteosarcoma (OS) is a highly aggressive malignancy with less than 30% 5-year survival rate among patients with metastatic or recurrent cancer. However, the treatment for osteosarcoma has not been modified in the last three decades. Oncolytic viruses have shown encouraging results in pre-clinical trials, but have failed to translate into high therapeutic efficacy in clinical trials. In this study, we will determine the therapeutic effect of combining PI3K inhibitor with an oncolytic virus against osteosarcoma. Material and Methods: Osteosarcoma cell lines and xenograft model were treated with ZSTK474 and/or VSVΔ51, the tumor suppressive ability was verified by in vitro cytotoxicity experiments and in vivo antitumor activity experiments, and the antitumor mechanism was explored through the study of apoptosis-related signaling pathways. Results: ZSTK474 sensitized the osteosarcoma cells to VSVΔ51, and augmented apoptosis via endoplasmic reticulum stress. The combination treatment also showed greater in vivo tumor inhibition compared to either ZSTK474 or VSVΔ51 alone, and significantly enhanced the tumor infiltration of immune cells. Conclusion: PI3K inhibitors combined with oncolytic virus is a promising strategy against osteosarcoma.


2013 ◽  
Vol 56 (7) ◽  
pp. 2911-2935 ◽  
Author(s):  
Khondaker M. Rahman ◽  
Paul J. M. Jackson ◽  
Colin H. James ◽  
B. Piku Basu ◽  
John A. Hartley ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document